Subjects -> MEDICAL SCIENCES (Total: 8359 journals)
    - ANAESTHESIOLOGY (119 journals)
    - CARDIOVASCULAR DISEASES (329 journals)
    - DENTISTRY (288 journals)
    - ENDOCRINOLOGY (148 journals)
    - FORENSIC SCIENCES (41 journals)
    - HEMATOLOGY (153 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (164 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2268 journals)
    - NURSES AND NURSING (356 journals)
    - OBSTETRICS AND GYNECOLOGY (202 journals)
    - ONCOLOGY (377 journals)
    - OTORHINOLARYNGOLOGY (80 journals)
    - PATHOLOGY (96 journals)
    - PEDIATRICS (270 journals)
    - PSYCHIATRY AND NEUROLOGY (813 journals)
    - RESPIRATORY DISEASES (102 journals)
    - RHEUMATOLOGY (76 journals)
    - SPORTS MEDICINE (78 journals)
    - SURGERY (393 journals)

RESPIRATORY DISEASES (102 journals)                     

Showing 1 - 102 of 102 Journals sorted alphabetically
Advances in Respiratory Medicine     Open Access   (Followers: 7)
American Journal of Respiratory and Critical Care Medicine     Full-text available via subscription   (Followers: 254)
American Journal of Respiratory Cell and Molecular Biology     Full-text available via subscription   (Followers: 20)
American Review of Respiratory Disease     Full-text available via subscription   (Followers: 4)
Angiologia e Cirurgia Vascular     Open Access   (Followers: 1)
Annals of the American Thoracic Society     Full-text available via subscription   (Followers: 16)
Annals of Thoracic Medicine     Open Access   (Followers: 6)
Archivos de Bronconeumología     Full-text available via subscription  
Archivos de Bronconeumología (English Edition)     Full-text available via subscription   (Followers: 1)
Asthma Research and Practice     Open Access   (Followers: 1)
BMC Pulmonary Medicine     Open Access   (Followers: 4)
BMJ Open Respiratory Research     Open Access   (Followers: 5)
Breathe     Open Access   (Followers: 4)
Canadian Journal of Respiratory, Critical Care, and Sleep Medicine     Hybrid Journal  
Canadian Respiratory Journal     Open Access   (Followers: 2)
Case Reports in Pulmonology     Open Access   (Followers: 3)
Chest     Full-text available via subscription   (Followers: 100)
Chest Disease Reports     Open Access   (Followers: 2)
Chronic Respiratory Disease     Hybrid Journal   (Followers: 9)
Clinical Lung Cancer     Hybrid Journal   (Followers: 5)
Clinical Medicine Insights : Circulatory, Respiratory and Pulmonary Medicine     Open Access   (Followers: 3)
Clinical Pulmonary Medicine     Hybrid Journal   (Followers: 2)
COPD Research and Practice     Open Access   (Followers: 1)
COPD: Journal of Chronic Obstructive Pulmonary Disease     Hybrid Journal   (Followers: 15)
Current Opinion in Pulmonary Medicine     Hybrid Journal   (Followers: 10)
Current Pulmonology Reports     Hybrid Journal  
Current Research in Tuberculosis     Open Access   (Followers: 3)
Current Respiratory Care Reports     Hybrid Journal   (Followers: 1)
Current Respiratory Medicine Reviews     Hybrid Journal   (Followers: 5)
Der Pneumologe     Hybrid Journal   (Followers: 1)
Egyptian Journal of Chest Diseases and Tuberculosis     Open Access   (Followers: 3)
ERJ Open Research     Open Access   (Followers: 2)
Eurasian Journal of Pulmonology     Open Access  
European Clinical Respiratory Journal     Open Access   (Followers: 3)
European Respiratory Journal     Full-text available via subscription   (Followers: 38)
European Respiratory Review     Open Access   (Followers: 7)
Experimental Lung Research     Hybrid Journal  
Expert Review of Respiratory Medicine     Hybrid Journal   (Followers: 5)
Heart & Lung: The Journal of Acute and Critical Care     Hybrid Journal   (Followers: 11)
Heart, Lung and Circulation     Full-text available via subscription   (Followers: 9)
Indian Journal of Respiratory Care     Open Access   (Followers: 3)
Indian Journal of Tuberculosis     Full-text available via subscription  
Influenza and Other Respiratory Viruses     Open Access   (Followers: 3)
International Journal of Chronic Obstructive Pulmonary Disease     Open Access   (Followers: 3)
Journal of Association of Chest Physicians     Open Access   (Followers: 2)
Journal of Asthma     Hybrid Journal   (Followers: 4)
Journal of Asthma Allergy Educators     Hybrid Journal   (Followers: 4)
Journal of Bronchology & Interventional Pulmonology     Hybrid Journal   (Followers: 3)
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases     Open Access  
Journal of Heart and Lung Transplantation     Hybrid Journal   (Followers: 12)
Journal of Respiratory Medicine     Open Access   (Followers: 4)
Journal of Respiratory Research     Open Access   (Followers: 1)
Journal of Tuberculosis Research     Open Access   (Followers: 1)
Jurnal Respirasi     Open Access  
Karger Kompass Pneumologie     Full-text available via subscription   (Followers: 1)
Kindheit und Entwicklung     Hybrid Journal  
Lung     Hybrid Journal   (Followers: 2)
Lung Cancer     Hybrid Journal   (Followers: 15)
Lung Cancer International     Open Access   (Followers: 2)
Lung Cancer: Targets and Therapy     Open Access   (Followers: 3)
Lung India     Open Access   (Followers: 1)
Multidisciplinary Respiratory Medicine     Open Access   (Followers: 4)
npj Primary Care Respiratory Medicine     Open Access   (Followers: 2)
Open Journal of Respiratory Diseases     Open Access   (Followers: 1)
Open Respiratory Medicine Journal     Open Access   (Followers: 1)
Paediatric Respiratory Reviews     Hybrid Journal   (Followers: 11)
Pediatric Quality & Safety     Open Access  
Pediatric Respirology and Critical Care Medicine     Open Access   (Followers: 1)
Pulmonary Circulation     Open Access   (Followers: 4)
Pulmonary Medicine     Open Access   (Followers: 2)
Pulmonary Pharmacology & Therapeutics     Hybrid Journal   (Followers: 2)
Pulmonary Therapy     Open Access   (Followers: 1)
Pulmonology and Respiratory Research     Open Access   (Followers: 1)
Respiratory Care     Full-text available via subscription   (Followers: 10)
Respiratory Investigation     Full-text available via subscription  
Respiratory Medicine     Hybrid Journal   (Followers: 17)
Respiratory Medicine : X     Open Access  
Respiratory Medicine Case Reports     Open Access  
Respiratory Medicine CME     Hybrid Journal  
Respiratory Medicine Extra     Full-text available via subscription   (Followers: 1)
Respiratory Physiology & Neurobiology     Hybrid Journal   (Followers: 4)
Respiratory Research     Open Access   (Followers: 1)
Respirology     Hybrid Journal   (Followers: 5)
Respirology Case Reports     Open Access  
Revista Americana de Medicina Respiratoria     Open Access  
Revista Chilena de Enfermedades Respiratorias     Open Access  
Revista Inspirar     Open Access  
Revista ORL     Open Access  
Revista Portuguesa de Pneumologia     Open Access  
Sarcoidosis Vasculitis and Diffuse Lung Disese     Full-text available via subscription   (Followers: 3)
Seminars in Respiratory and Critical Care Medicine     Hybrid Journal   (Followers: 14)
Sleep Medicine Reviews     Hybrid Journal   (Followers: 17)
The Clinical Respiratory Journal     Hybrid Journal   (Followers: 3)
The International Journal of Tuberculosis and Lung Disease     Full-text available via subscription   (Followers: 8)
The Lancet Respiratory Medicine     Full-text available via subscription   (Followers: 32)
Therapeutic Advances in Chronic Disease     Open Access   (Followers: 7)
Therapeutic Advances in Respiratory Disease     Open Access   (Followers: 1)
Thorax     Hybrid Journal   (Followers: 37)
Translational Respiratory Medicine     Open Access   (Followers: 1)
Tuberculosis     Hybrid Journal   (Followers: 12)
Tuberculosis Research and Treatment     Open Access   (Followers: 3)
Пульмонология     Full-text available via subscription  


Similar Journals
Journal Cover
European Respiratory Review
Journal Prestige (SJR): 1.973
Citation Impact (citeScore): 4
Number of Followers: 7  

  This is an Open Access Journal Open Access journal
ISSN (Print) 0905-9180 - ISSN (Online) 1600-0617
Published by European Respiratory Society Homepage  [4 journals]
  • ERS statement on standardisation of cardiopulmonary exercise testing in
           chronic lung diseases

    • Authors: Radtke, T; Crook, S, Kaltsakas, G, Louvaris, Z, Berton, D, Urquhart, D. S, Kampouras, A, Rabinovich, R. A, Verges, S, Kontopidis, D, Boyd, J, Tonia, T, Langer, D, De Brandt, J, Goërtz, Y. M. J, Burtin, C, Spruit, M. A, Braeken, D. C. W, Dacha, S, Franssen, F. M. E, Laveneziana, P, Eber, E, Troosters, T, Neder, J. A, Puhan, M. A, Casaburi, R, Vogiatzis, I, Hebestreit, H.
      Pages: 180101 - 180101
      Abstract: The objective of this document was to standardise published cardiopulmonary exercise testing (CPET) protocols for improved interpretation in clinical settings and multicentre research projects. This document: 1) summarises the protocols and procedures used in published studies focusing on incremental CPET in chronic lung conditions; 2) presents standard incremental protocols for CPET on a stationary cycle ergometer and a treadmill; and 3) provides patients' perspectives on CPET obtained through an online survey supported by the European Lung Foundation. We systematically reviewed published studies obtained from EMBASE, Medline, Scopus, Web of Science and the Cochrane Library from inception to January 2017. Of 7914 identified studies, 595 studies with 26 523 subjects were included. The literature supports a test protocol with a resting phase lasting at least 3 min, a 3-min unloaded phase, and an 8- to 12-min incremental phase with work rate increased linearly at least every minute, followed by a recovery phase of at least 2–3 min. Patients responding to the survey (n=295) perceived CPET as highly beneficial for their diagnostic assessment and informed the Task Force consensus. Future research should focus on the individualised estimation of optimal work rate increments across different lung diseases, and the collection of robust normative data.
      Keywords: Lung biology and experimental studies
      PubDate: 2019-12-18T00:05:13-08:00
      DOI: 10.1183/16000617.0101-2018
      Issue No: Vol. 28, No. 154 (2019)
  • Management of pulmonary toxicity associated with immune checkpoint

    • Authors: Delaunay, M; Prevot, G, Collot, S, Guilleminault, L, Didier, A, Mazieres, J.
      Pages: 190012 - 190012
      Abstract: Immunotherapy has become a standard of care in oncology, following the recent approvals of cytotoxic T-lymphocyte-associated protein-4 and programmed cell death-1 inhibitors in lung cancer, melanoma, renal cell carcinoma, Hodgkin's lymphoma, bladder, head and neck cancers. Besides their efficacy, these agents also generate specific immune-related adverse events. Due to the increasing prescription of immune-checkpoint inhibitors, the incidence of immune toxicity will continue to rise. The awareness of immune-related adverse events is key to ensuring both diagnosis and management of the possible serious adverse events. Although severe immune-related adverse events remain rare, they can lead to discontinued treatment or to death if they are not forecasted and managed properly. Even if lung toxicity is not the most frequent adverse event, it remains critical as it can be life-threatening. Herein, the main aspects of pulmonary toxicity are reviewed and guidelines are also proposed in order to manage the possible side-effects.
      Keywords: Pulmonary pharmacology and therapeutics
      PubDate: 2019-11-06T03:24:41-08:00
      DOI: 10.1183/16000617.0012-2019
      Issue No: Vol. 28, No. 154 (2019)
  • Sex differences in obstructive sleep apnoea

    • Authors: Bonsignore, M. R; Saaresranta, T, Riha, R. L.
      Pages: 190030 - 190030
      Abstract: Obstructive sleep apnoea (OSA) and obstructive sleep apnoea/hypopnoea syndrome (OSAHS) have long been considered predominantly male-related conditions. The clinical presentation of sleep disordered breathing in females differs from males and can vary with age and physiological status, e.g. menopause and pregnancy. Overall, females appear to be more symptomatic, with lower apnoea–hypopnoea index scores compared to males. Furthermore, they appear to have more prolonged partial upper airway obstruction, and may report insomnia as a symptom of OSAHS more frequently. As a consequence of these differences in clinical presentation, females with sleep disordered breathing are often underdiagnosed and undertreated compared to males. This review is aimed at discussing the epidemiology, clinical presentation, pathophysiology and hormonal and metabolic differences in females who present with OSA/OSAHS in comparison to males.
      Keywords: Sleep medicine
      PubDate: 2019-11-06T03:24:41-08:00
      DOI: 10.1183/16000617.0030-2019
      Issue No: Vol. 28, No. 154 (2019)
  • Non-sleepy obstructive sleep apnoea: to treat or not to treat'

    • Authors: Altintas, N; Riha, R. L.
      Pages: 190031 - 190031
      Abstract: Non-sleepy obstructive sleep apnoea (OSA) is thought to have a prevalence of around 20–25% in industrialised countries. However, the question of whether it should be routinely treated or not is controversial. This review collates the results from recent randomised controlled trials addressing OSA and examines whether treating the condition leads to improvements in quality of life and reduced cardiometabolic dysfunction, comorbidities generally attributed to untreated obstructive sleep apnoea/hypopnoea syndrome.
      Keywords: Sleep medicine
      PubDate: 2019-12-23T01:00:19-08:00
      DOI: 10.1183/16000617.0031-2019
      Issue No: Vol. 28, No. 154 (2019)
  • Use of pedometers as a tool to promote daily physical activity levels in
           patients with COPD: a systematic review and meta-analysis

    • Authors: Armstrong, M; Winnard, A, Chynkiamis, N, Boyle, S, Burtin, C, Vogiatzis, I.
      Pages: 190039 - 190039
      Abstract: The aim of this study was to examine the use of pedometers as a tool to promote daily physical activity levels in patients with COPD.A systematic review meta-analysis of pedometer physical activity promotion in patients with COPD was conducted. Medline/PubMed, Cochrane Library, Web of Science and CINAHL were searched from inception to January 2019. The search strategy included the following keywords: physical activity promotion, pulmonary rehabilitation and daily physical activity. The eligibility criteria for selecting studies were randomised controlled trials reporting pedometer physical activity promotion in patients with COPD.Improvements in steps per day were found with pedometer physical activity promotion either standalone (n=12, mean 0.53 (95% CI 0.29–0.77); p=0.00001) or alongside pulmonary rehabilitation (n=7, 0.51 (0.13–0.88); p=0.006). A subgroup analysis reported significant differences in the promotion of physical activity based on baseline physical activity levels and the type of instrument used to assess levels of physical activity.Future trials should consider the way in which pedometers are used to promote physical activity to inform clinical practice in the setting of pulmonary rehabilitation.
      Keywords: COPD and smoking
      PubDate: 2019-11-13T03:52:51-08:00
      DOI: 10.1183/16000617.0039-2019
      Issue No: Vol. 28, No. 154 (2019)
  • Precision medicine is coming to town: personalising home ventilatory
           equipment in COPD patients with chronic hypercapnic respiratory failure

    • Authors: Gonzalez-Bermejo, J; Nava, S, Rabec, C, Vega, M. L.
      Pages: 190043 - 190043
      Abstract: Discharging a chronic critically ill patient is a risky procedure if the clinician does not have full control of his prescription. This is even more important when applying a machine to replace a failing organ, as is the case for home ventilation. Even if modern home ventilators fulfil quality and safety criteria and, ‘on paper’, ventilators and masks look very similar, performance and scenarios of applicability are not always equivalent. In the case of ventilators, the type of circuit, accessories provided and available modes vary between devices. Bench studies comparing ventilators have shown large differences in triggering, rise time, pressurisation capacities, maximal flow provided, cycling and level of authorised expiratory positive airway pressure. Automated algorithms to deal with leaks also vary and have not been sufficiently evaluated. In the case of interfaces, the choice of mask requires careful evaluation of the underlying disease and of the type of ventilator and circuit, which could have a potentially major impact on patient compliance and clinical effectiveness. This could explain different results in the same clinical situation. The choice of ventilator and type of mask represents a medical prescription and should be respected by the provider and not subject to financial constraints.
      Keywords: COPD and smoking
      PubDate: 2019-11-06T03:24:41-08:00
      DOI: 10.1183/16000617.0043-2019
      Issue No: Vol. 28, No. 154 (2019)
  • Lung clearance index: assessment and utility in children with asthma

    • Authors: Nuttall, A. G. L; Velasquez, W, Beardsmore, C. S, Gaillard, E. A.
      Pages: 190046 - 190046
      Abstract: There is increasing evidence that ventilation heterogeneity and small airway disease are significant factors in asthma, with evidence suggesting that the small airways are involved from an early stage in childhood asthma. Spirometry is commonly used to monitor lung function in asthmatics; however, it is not sensitive to small airway disease. There has been renewed interest in multibreath washout (MBW) tests, with recognition of the lung clearance index (LCI) as a global index of abnormality in gas mixing of the lungs that therefore also reflects small airway disease. This review summarises the technical and practical aspects of the MBW/LCI in children, and the differences between commercially available equipment. Children with severe asthma are more likely to have an abnormal LCI, whereas most children with mild-to-moderate asthma have an LCI within the normal range, but slightly higher than age-matched healthy controls. Monitoring children with asthma with MBW alongside standard spirometry may provide useful additional information.
      Keywords: Asthma and allergy
      PubDate: 2019-11-20T01:31:48-08:00
      DOI: 10.1183/16000617.0046-2019
      Issue No: Vol. 28, No. 154 (2019)
  • Sphingolipids in COPD

    • Authors: Chakinala, R. C; Khatri, A, Gupta, K, Koike, K, Epelbaum, O.
      Pages: 190047 - 190047
      Abstract: Sphingolipids are a distinct class of lipid molecules widely found in nature, principally as cell membrane constituents. After initial uncertainty about their function, sphingolipids have been increasingly recognised to be metabolically active entities involved in many biological processes, including the control of inflammation. Their role as mediators of inflammation may have significant implications for a range of lung diseases in which inflammation is a central element of pathogenesis. Chronic obstructive pulmonary disease (COPD), a highly prevalent and morbid condition predominantly affecting cigarette smokers, is a prime example of a respiratory illness with an inflammatory component. Understandably, sphingolipids have received growing attention for their increasingly demonstrated role in the pathophysiology of COPD. The present review aims to be among the first to focus exclusively on the connection between sphingolipids and lung inflammation in COPD, providing the reader with a clinically oriented synopsis of this intriguing association.
      Keywords: COPD and smoking
      PubDate: 2019-11-06T03:24:41-08:00
      DOI: 10.1183/16000617.0047-2019
      Issue No: Vol. 28, No. 154 (2019)
  • Sarcopenia in COPD: a systematic review and meta-analysis

    • Authors: Benz, E; Trajanoska, K, Lahousse, L, Schoufour, J. D, Terzikhan, N, De Roos, E, de Jonge, G. B, Williams, R, Franco, O. H, Brusselle, G, Rivadeneira, F.
      Pages: 190049 - 190049
      Abstract: COPD is associated with a progressive loss of muscle mass and function. However, there is an unmet need to define and standardise methods to estimate the prevalence of sarcopenia in COPD patients.We performed a systematic review and meta-analysis of the prevalence of this extrapulmonary manifestation in COPD patients. We searched Embase, Medline (Ovid), CINAHL (EBSCO), Web of Science, Scopus and Google Scholar for studies published up to January 17, 2019, assessing sarcopenia in COPD patients based on low muscle mass and decreased muscle function. Interventional studies, in vitro experiments, protocols or reviews and meta-analyses were excluded. We estimated heterogeneity (I2) and assessed significance (Q) using a Chi-squared test for estimates obtained from random-effects models.4465 articles were initially identified. After removing the duplicates and applying the selection criteria, we reviewed 62 full-text articles. Finally, 10 articles (n=2565 COPD patients) were included in this systematic review and meta-analyses. Overall, the prevalence of sarcopenia in patients with COPD was 21.6% (95% CI 14.6–30.9%, I2=94%), ranging from 8% in population-based to 21% in clinic-based studies, and 63% in COPD patients residing in nursing homes.Sarcopenia is frequently observed in COPD patients, with varying prevalence across population settings. Sarcopenia in COPD should be assessed using standardised tests and cut-off points from sarcopenia consensus criteria for clinical practice and international comparisons.
      Keywords: COPD and smoking
      PubDate: 2019-11-13T03:52:51-08:00
      DOI: 10.1183/16000617.0049-2019
      Issue No: Vol. 28, No. 154 (2019)
  • Learning from registries in pulmonary arterial hypertension: pitfalls and

    • Authors: Swinnen, K; Quarck, R, Godinas, L, Belge, C, Delcroix, M.
      Pages: 190050 - 190050
      Abstract: Pulmonary arterial hypertension is a rare and incurable chronic disease characterised by a progressive increase in pulmonary vascular resistance and right heart failure. Patient registries collecting observational data can be of great value in the understanding of clinical problems. While clinical trials provide data in selected patient populations, registries better depict real-life practice. This review aims to reflect the input of patient registries in the general knowledge of the disease. Advances in epidemiology of the different subgroups, including data on incidence and/or prevalence, increasing age at presentation and stagnating diagnostic delay are reported. The importance of haemodynamic definition criteria and cardiac comorbidities are underscored. The review also shows the major transformation that pulmonary arterial hypertension therapeutic management has undergone, with still insufficient use of combination therapies; consecutive improvement in outcome; upcoming evidence in disfavour of anticoagulation; and validity of the available risk-stratification tools derived from large registries. Product registries are also briefly presented. Finally, the benefits of registries and methodological aspects are discussed, including immortal time bias, registry data quality and recommendations from EU organisations (EUCERD and PARENT).
      Keywords: Interstitial and orphan lung disease
      PubDate: 2019-12-18T00:05:13-08:00
      DOI: 10.1183/16000617.0050-2019
      Issue No: Vol. 28, No. 154 (2019)
  • The biology of pulmonary exacerbations in bronchiectasis

    • Authors: Amati, F; Simonetta, E, Gramegna, A, Tarsia, P, Contarini, M, Blasi, F, Aliberti, S.
      Pages: 190055 - 190055
      Abstract: Bronchiectasis is a heterogeneous chronic disease. Heterogeneity characterises bronchiectasis not only in the stable state but also during exacerbations, despite evidence on clinical and biological aspects of bronchiectasis, exacerbations still remain poorly understood.Although the scientific community recognises that bacterial infection is a cornerstone in the development of bronchiectasis, there is a lack of data regarding other trigger factors for exacerbations. In addition, a huge amount of data suggest a primary role of neutrophils in the stable state and exacerbation of bronchiectasis, but the inflammatory reaction involves many other additional pathways. Cole's vicious cycle hypothesis illustrates how airway dysfunction, airway inflammation, infection and structural damage are linked. The introduction of the concept of a "vicious vortex" stresses the complexity of the relationships between the components of the cycle. In this model of disease, exacerbations work as a catalyst, accelerating the progression of disease. The roles of microbiology and inflammation need to be considered as closely linked and will need to be investigated in different ways to collect samples. Clinical and translational research is of paramount importance to achieve a better comprehension of the pathophysiology of bronchiectasis, microbiology and inflammation both in the stable state and during exacerbations.
      Keywords: CF and non-CF bronchiectasis
      PubDate: 2019-11-20T01:31:48-08:00
      DOI: 10.1183/16000617.0055-2019
      Issue No: Vol. 28, No. 154 (2019)
  • Thoracic ultrasound competence for ultrasound-guided pleural procedures

    • Authors: McCracken, D. J; Laursen, C. B, Barker, G, Gleeson, F. V, Cullen, K. M, Rahman, N. M.
      Pages: 190090 - 190090
      Abstract: Focused thoracic ultrasound has become essential in the guidance and direction of pleural interventions to reduce unwanted complications and as a result now forms a crucial component of physician training. Current training standards along with assessment methods vary widely, and are often not robust enough to ensure adequate competence.This review assesses the current state of training and assessment of thoracic ultrasound competence in various settings, allowing comparison with alternative competency based programmes. Future directions for training and assessment of thoracic ultrasound competence are discussed.
      Keywords: Lung imaging
      PubDate: 2019-12-23T01:00:19-08:00
      DOI: 10.1183/16000617.0090-2019
      Issue No: Vol. 28, No. 154 (2019)
  • CD8+ Tc2 cells: underappreciated contributors to severe asthma

    • Authors: Hinks, T. S. C; Hoyle, R. D, Gelfand, E. W.
      Pages: 190092 - 190092
      Abstract: The complexity of asthma is underscored by the number of cell types and mediators implicated in the pathogenesis of this heterogeneous syndrome. Type 2 CD4+ T-cells (Th2) and more recently, type 2 innate lymphoid cells dominate current descriptions of asthma pathogenesis. However, another important source of these type 2 cytokines, especially interleukin (IL)-5 and IL-13, are CD8+ T-cells, which are increasingly proposed to play an important role in asthma pathogenesis, because they are abundant and are comparatively insensitive to corticosteroids. Many common triggers of asthma exacerbations are mediated via corticosteroid-resistant pathways involving neutrophils and CD8+ T-cells. Extensive murine data reveal the plasticity of CD8+ T-cells and their capacity to enhance airway inflammation and airway dysfunction. In humans, Tc2 cells are predominant in fatal asthma, while in stable state, severe eosinophilic asthma is associated with greater numbers of Tc2 than Th2 cells in blood, bronchoalveolar lavage fluid and bronchial biopsies. Tc2 cells strongly express CRTH2, the receptor for prostaglandin D2, the cysteinyl leukotriene receptor 1 and the leukotriene B4 receptor. When activated, these elicit Tc2 cell chemotaxis and production of chemokines and type 2 and other cytokines, resulting directly or indirectly in eosinophil recruitment and survival. These factors position CD8+ Tc2 cells as important and underappreciated effector cells contributing to asthma pathogenesis. Here, we review recent advances and new insights in understanding the pro-asthmatic functions of CD8+ T-cells in eosinophilic asthma, especially corticosteroid-resistant asthma, and the molecular mechanisms underlying their pathologic effector function.
      Keywords: Asthma and allergy
      PubDate: 2019-11-20T01:31:48-08:00
      DOI: 10.1183/16000617.0092-2019
      Issue No: Vol. 28, No. 154 (2019)
  • The future of bronchodilation: looking for new classes of bronchodilators

    • Authors: Cazzola, M; Rogliani, P, Matera, M. G.
      Pages: 190095 - 190095
      Abstract: Available bronchodilators can satisfy many of the needs of patients suffering from airway disorders, but they often do not relieve symptoms and their long-term use raises safety concerns. Therefore, there is interest in developing new classes that could help to overcome the limits that characterise the existing classes.At least nine potential new classes of bronchodilators have been identified: 1) selective phosphodiesterase inhibitors; 2) bitter-taste receptor agonists; 3) E-prostanoid receptor 4 agonists; 4) Rho kinase inhibitors; 5) calcilytics; 6) agonists of peroxisome proliferator-activated receptor-; 7) agonists of relaxin receptor 1; 8) soluble guanylyl cyclase activators; and 9) pepducins. They are under consideration, but they are mostly in a preclinical phase and, consequently, we still do not know which classes will actually be developed for clinical use and whether it will be proven that a possible clinical benefit outweighs the impact of any adverse effect.It is likely that if developed, these new classes may be a useful addition to, rather than a substitution of, the bronchodilator therapy currently used, in order to achieve further optimisation of bronchodilation.
      Keywords: Pulmonary pharmacology and therapeutics
      PubDate: 2019-12-23T01:00:19-08:00
      DOI: 10.1183/16000617.0095-2019
      Issue No: Vol. 28, No. 154 (2019)
  • Pulmonary arterial hypertension registries: past, present and into the

    • Authors: Weatherald, J; Reis, A, Sitbon, O, Humbert, M.
      Pages: 190128 - 190128
      Abstract: Disease registries are important sources of real-world evidence that inform clinical practice and health policy, particularly when randomised controlled trials do not exist [1]. Much of what we know today about pulmonary arterial hypertension (PAH) has come from observational studies from national and/or international disease registries.
      Keywords: Interstitial and orphan lung disease
      PubDate: 2019-12-18T00:05:13-08:00
      DOI: 10.1183/16000617.0128-2019
      Issue No: Vol. 28, No. 154 (2019)
  • "Antifibrotic therapy for fibrotic lung disease beyond idiopathic
           pulmonary fibrosis." Bridget F. Collins and Ganesh Raghu. Eur Respir Rev
           2019; 28: 190022.

    • Pages: 195022 - 195022
      PubDate: 2019-11-13T03:52:51-08:00
      DOI: 10.1183/16000617.5022-2019
      Issue No: Vol. 28, No. 154 (2019)
  • "National and regional asthma programmes in Europe." Olof Selroos, Maciej
           Kupczyk, Piotr Kuna, Piotr Łacwik, Jean Bousquet, David Brennan, Susanna
           Palkonen, Javier Contreras, Mark FitzGerald, Gunilla Hedlin, Sebastian L.
           Johnston, Renaud Louis, Leanne Metcalf, Samantha Walker, Antonio
           Moreno-Galdo, Nikolaos G. Papadopoulos, Jose Rosado-Pinto, Pippa Powell
           and Tari Haahtela. Eur Respir Rev 2015; 24: 474-483.

    • Pages: 195081 - 195081
      PubDate: 2019-12-23T01:00:19-08:00
      DOI: 10.1183/16000617.5081-2014
      Issue No: Vol. 28, No. 154 (2019)
  • "Central sleep apnoea and periodic breathing in heart failure: prognostic
           significance and treatment options." Winfried Randerath, Oana Deleanu,
           Sophia Schiza and Jean-Louis Pepin. Eur Respir Rev 2019; 28: 190084.

    • Pages: 195084 - 195084
      PubDate: 2019-11-13T03:52:51-08:00
      DOI: 10.1183/16000617.5084-2019
      Issue No: Vol. 28, No. 154 (2019)
  • "Cellular mechanisms underlying steroid-resistant asthma." Ridhima Wadhwa,
           Kamal Dua, Ian M. Adcock, Jay C. Horvat, Richard Y. Kim and Philip M.
           Hansbro. Eur Respir Rev 2019; 28: 190021.

    • Pages: 195096 - 195096
      PubDate: 2019-11-13T03:52:51-08:00
      DOI: 10.1183/16000617.5096-2019
      Issue No: Vol. 28, No. 154 (2019)
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762

Your IP address:
Home (Search)
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-